OncoMatch/Clinical Trials/NCT05348213
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Is NCT05348213 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for diffuse large b cell lymphoma.
Treatment: Zanubrutinib plus R-ICE · Decitabine plus R-ICE · Chidamide plus R-ICE · Tofacitinib plus R-ICE · Pomalidomide plus R-ICE — A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-lymphoma therapy — first-line
Prior treatment with sufficient first-line anti-lymphoma therapy, no remission within 90 days of the last administration, or disease progression after sufficient first-line anti-lymphoma therapy
Cannot have received: anti-lymphoma therapy
Exception: ≥2 weeks since the last anti-lymphoma therapy
no current anti-lymphoma therapy (≥2 weeks since the last anti-lymphoma therapy)
Cannot have received: organ transplant
Patients who have received organ transplants
Cannot have received: surgery
Exception: grade II or above surgery within three weeks before treatment
Those who have received grade II or above surgery within three weeks before treatment
Lab requirements
Blood counts
Absolute value of neutrophil count ≥1500/mm3; Platelet count ≥75,000/mm3
Kidney function
creatinine clearance rate ≥60ml/min
Liver function
Total bilirubin ≤2× ULN; AST and ALT ≤3× ULN
Cardiac function
No cardiac dysfunction
No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment): Absolute value of neutrophil count ≥1500/mm3; Platelet count ≥75,000/mm3; Total bilirubin ≤2× ULN; AST and ALT ≤3× ULN; creatinine clearance rate ≥60ml/min; No cardiac dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify